Exelixis Inc (EXEL)vsRegeneron Pharmaceuticals Inc (REGN)
EXEL
Exelixis Inc
$56.12
-2.28%
HEALTHCARE · Cap: $14.62B
REGN
Regeneron Pharmaceuticals Inc
$781.49
-1.48%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 538% more annual revenue ($15.53B vs $2.44B). EXEL leads profitability with a 35.3% profit margin vs 27.9%. REGN appears more attractively valued with a PEG of 1.31. EXEL earns a higher WallStSmart Score of 70/100 (B-).
EXEL
Strong Buy70
out of 100
Grade: B-
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.9%
Fair Value
$164.33
Current Price
$56.12
$108.21 discount
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$781.49
$622.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 47 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 39.5%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 26.2% YoY
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.3% and operating margin at 39.5%. Revenue growth of 10.6% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
EXEL profiles as a mature stock while REGN is a growth play — different risk/reward profiles.
EXEL carries more volatility with a beta of 0.42 — expect wider price swings.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
EXEL scores higher overall (70/100 vs 66/100), backed by strong 35.3% margins and 10.6% revenue growth. REGN offers better value entry with a 44.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?